During the COVID-19 pandemic, there has been a lot of experimentation with new technologies for remote patient monitoring (RPM) to improve adherence and survival, according to Gregory Vidal, MD, PhD, medical oncologist specializing in breast cancer at West Cancer Center.
During the COVID-19 pandemic, there has been a lot of experimentation with new technologies for remote patient monitoring to improve adherence and survival, according to Gregory Vidal, MD, PhD, medical oncologist specializing in breast cancer at West Cancer Center.
Transcript
What technology are you typically using for remote patient monitoring with cancer patients?
So, a lot of the technology is early in development. Actively in the clinical setting, we do sort of teleconsultation using computers, iPads, and through different means. I think that's the one that I use most frequently. So, every day in clinic I have a certain percentage of my clinic patients for whom I do teleconsultation.
Our patients also use our portal to report patient-reported outcomes. We use at our center a PCM—patient care monitor—that allows patients, it's a validated tool, to report the outcomes. And we've placed that on our portal, so patients actually are able to use that that way. Another aspect of remote monitoring that I've been involved in is a registry called Neat-HER with Puma [Biotechnology], where we're trying to gather information on how patients use the drug, what are their side effects, and also if there is anything new going on with the drug through remote monitoring. We use a portal called PicnicHealth, where all of these patients can gather your information and make it available for them and also available for the registry. And they can also pass that information on to the other practitioners who they go to visit.
And then in the clinical trial setting, I do have about 300 or so patients who participate in our clinical trial, utilizing an app that we're now testing, which is trying to investigate as to whether prompting patients—patients reporting their outcomes, which then gets to the care team, and the care team then follows back up—whether or not that improves adherence and, ultimately, survival for those patients.
Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL
December 26th 2024A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.
Listen
HS Treatment Goals: Better Quality of Life, Not Just Control
January 3rd 2025For part 3 of our discussion with Chris Sayed, MD, we tackle several important topics in the hidradenitis suppurative (HS) and inflammatory disease space: patient quality of life, medication and treatment goals, and the possibility of a cure.
Read More
Dr Yehuda Handelsman: DCRM Guidelines Are Shaping Integrated, Global CRM Care
January 3rd 2025In part 2 of our interview, Yehuda Handelsman, MD, discusses how cardiorenalmetabolic (CRM) disease management is advancing with the 2022 Diabetes, Cardiorenal, and Metabolic (DCRM) multispecialty practice recommendations and the updated DCRM 2.0 guidelines.
Read More
Stripped of Fucose, Powerful Monoclonal Antibody Shows Promising Results in MDS Dosing Study
January 2nd 2025Nicole Grieselhuber, MD, PhD, of The Ohio State University, discusses results from Part D of a dosing study involving patients with previously untreated higher-risk myelodysplastic syndrome (MDS) who were treated with a combination of SEA-CD70 and azacitidine.
Read More